Middle East & AfricaENPublic regulatory overview
Kenya
Market Overview Population: Approximately 56 million (2024), the largest economy in East Africa Healthcare System: Public healthcare system (countylevel and national hospitals) + p...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Kenya
- Product line: Medical devices
- Regulator / source: Market Characteristics: A strategic hub for the East Africa region, with distribution networks covering neighboring countries including Uganda, Tanzania, Rwanda, and South Sudan; the high-end private medical market has strong demand for innovative devices; public procurement is centralized through KEMSA (Kenya Medical Supplies Authority); regulatory modernization is ongoing
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 56 million (2024), the largest economy in East Africa
- Healthcare System: Public healthcare system (county-level and national hospitals) + private healthcare (high-end private hospitals including Aga Khan Hospital, Nairobi Hospital, MP Shah Hospital, etc.); the National Hospital Insurance Fund (NHIF, now restructured as the Social Health Insurance Fund, SHIF) continues to expand coverage; healthcare resources are concentrated in Nairobi and coastal areas
- Market Characteristics: A strategic hub for the East Africa region, with distribution networks covering neighboring countries including Uganda, Tanzania, Rwanda, and South Sudan; the high-end private medical market has strong demand for innovative devices; public procurement is centralized through KEMSA (Kenya Medical Supplies Authority); regulatory modernization is ongoing
- Regulatory Maturity: Medium; the Pharmacy and Poisons Board (PPB) is transitioning toward a modern regulatory authority (renamed the Pharmacy and Poisons Board / Pharmacy Council; regulations continue to be updated); the East African Community (EAC) harmonization framework is being advanced
Regulatory Authority
- Competent Authority: Pharmacy and Poisons Board (PPB), operating under the Pharmacy and Poisons Act (Cap 244), subordinate to the Ministry of Health; medical devices are managed through PPB's Medical Devices Registration Department
- Official Portal: https://www.ppb.go.ke; online submission system: PPB eRegulations Portal (https://eregs.ppb.go.ke)
- Key Regulations:
- Pharmacy and Poisons Act Cap 244
- Medical Devices (Registration) Rules (multiple updates; refer to the latest version)
- Kenya Standard KS ISO 13485 (Medical Device Quality Management System standard, published by KEBS)
- East African Community Medical Devices Harmonization Framework (EAC framework; in progress)
- Kenya Bureau of Standards (KEBS): certain product categories require a KEBS Standards Compliance Certificate
Device Classification System
| Local Class | Risk Level | EU Equivalent | FDA Equivalent | Description |
|---|---|---|---|---|
| Class 1 | Low risk | EU Class I / FDA Class I | Simplified registration, basic document requirements | |
| Class 2 | Low-medium risk | EU Class IIa / FDA Class II | Standard registration; Technical File required | |
| Class 3 | Medium-high risk | EU Class IIb / FDA Class II–III | Full technical review | |
| Class 4 | High risk | EU Class III / FDA Class III | Most rigorous review; complete clinical evidence required |
Classification is based on GHTF classification principles (referencing GHTF SG1 documents); IVDs have a separate classification following the GHTF IVD classification framework.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.